---
title: "Morgan Stanley expects that the stock price of Kanglong Chemical will rise in the next 30 days, as the recent pullback has made short-term valuations attractive"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278805272.md"
description: "Morgan Stanley expects the stock price of Kanglong Chemical to rise in the next 30 days, as the recent pullback has made short-term valuations attractive. The company has signed a major commercial production contract with Eli Lilly, involving the production of Orforglipron formulations, with Eli Lilly committing to invest $3 billion in China. This contract is expected to accelerate Kanglong Chemical's profit growth from 2026 to 2027, with an estimated profit growth of about 10% in 2025. The stock is currently trading at a price-to-earnings ratio of 14 times for 2026, lower than the industry average of 20 times, and is given an \"Overweight\" rating with a target price of HKD 31"
datetime: "2026-03-12T02:00:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278805272.md)
  - [en](https://longbridge.com/en/news/278805272.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278805272.md)
---

# Morgan Stanley expects that the stock price of Kanglong Chemical will rise in the next 30 days, as the recent pullback has made short-term valuations attractive

Morgan Stanley's research report on technology predicts that the stock price of Kanglong Chemical (03759.HK) will rise in the next 30 days, as the recent decline in the stock has made short-term valuations attractive.

The firm indicated that the company has secured a major commercial production contract with Eli Lilly (LLY.US) for the production of Orforglipron formulations in China. Eli Lilly has committed to investing $3 billion in China over the next decade, with $200 million specifically allocated for Kanglong Chemical's capacity building, and there is potential for further expansion. Orforglipron is an experimental oral GLP-1 drug used by Eli Lilly for the treatment of type 2 diabetes and obesity, with its listing application submitted to the Chinese drug regulatory authority by the end of 2025.

The firm believes that the contract is expected to accelerate Kanglong Chemical's profit growth in 2026-27, with management anticipating a profit growth of about 10% in 2025. The stock is currently trading at a forecasted price-to-earnings ratio of 14 times for 2026, and Kanglong Chemical's H shares are currently valued below its peers (over 20 times). The firm has now assigned a "Buy" rating to Kanglong Chemical's H shares, with a target price of HKD 31

## Related News & Research

- [Casey Neistat’s guide to posting every day](https://longbridge.com/en/news/288318418.md)
- [Brazil Harvest Pressures Weigh on Coffee Prices](https://longbridge.com/en/news/288453077.md)
- [Alkem launches semaglutide pre-filled syringes in India at ₹350](https://longbridge.com/en/news/288468615.md)
- [Herbal Dispatch Reports First Quarter 2026 Results and Provides Business Update | LUFFF Stock News](https://longbridge.com/en/news/288228364.md)
- [Pfizer inks $10.5B oncology deal as Lilly expands vaccines](https://longbridge.com/en/news/288199750.md)